According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

# **Furosemide Injection Formulation**

| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.4     | 28.09.2024     | 9372650-00008 | Date of first issue: 27.08.2021 |

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

| 1.1 | Product identifier<br>Trade name                     | :   | Furosemide Injection Formulation                                      |  |  |  |
|-----|--|-----|---|--|--|--|
| 1.2 | Relevant identified uses of th                       | e s | ubstance or mixture and uses advised against                          |  |  |  |
|     | Use of the Sub-<br>stance/Mixture                    |     | Veterinary product  |  |  |  |
|     | Recommended restrictions on use                      | :   | Not applicable  |  |  |  |
| 1.3 | 1.3 Details of the supplier of the safety data sheet |     |   |  |  |  |
|     | Company  | :   | MSD<br>Walton Manor, Walton<br>MK7 7AJ Milton Keynes - United Kingdom |  |  |  |
|     | Telephone  | :   | +1-908-740-4000   |  |  |  |
|     | E-mail address of person responsible for the SDS     | :   | EHSDATASTEWARD@msd.com  |  |  |  |

### 1.4 Emergency telephone number

+1-908-423-6000

# **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Specific target organ toxicity - repeated exposure, Category 2

H373: May cause damage to organs through prolonged or repeated exposure.

### 2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Hazard pictograms



Signal word



# **Furosemide Injection Formulation**

| Versior<br>3.4 | Revision Date: 28.09.2024 | SDS Number<br>9372650-000 |  |
|----------------|---------------------------|---------------------------|--|
| Ha             | azard statements          | : H373                    | May cause damage to organs through prolonged or repeated exposure. |
| Pr             | ecautionary statements    | : <b>Response</b><br>P314 | : Get medical advice/ attention if you feel unwell.                |

Hazardous components which must be listed on the label:

Furosemide

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

# **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

### Components

| Chemical name | CAS-No.             | Classification  |             |
|---------------|---------------------|-----------------|-------------|
|               | EC-No.              |                 | (% w/w)     |
|               | Index-No.           |                 |             |
|               | Registration number |                 |             |
| Furosemide    | 54-31-9             | STOT RE 1; H372 | >= 1 - < 10 |
|               | 200-203-6           | (Kidney, Liver) |             |

For explanation of abbreviations see section 16.

# **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

| General advice             | : | In the case of accident or if you feel unwell, seek medical ad-<br>vice immediately.<br>When symptoms persist or in all cases of doubt seek medical<br>advice.                    |
|----------------------------|---|---|
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection,<br>and use the recommended personal protective equipment<br>when the potential for exposure exists (see section 8). |
| If inhaled                 | : | If inhaled, remove to fresh air.<br>Get medical attention if symptoms occur.  |
| In case of skin contact    | : | In case of contact, immediately flush skin with soap and plenty<br>of water.<br>Get medical attention if symptoms occur.  |
| In case of eye contact     | : | Flush eyes with water as a precaution.<br>Get medical attention if irritation develops and persists.  |



| Vers<br>3.4 | sion                | Revision Date:<br>28.09.2024      | -    | DS Number:<br>72650-00008   | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021  |  |
|-------------|---------------------|-----------------------------------|------|---|--|--|
|             | If swall            | owed                              | :    | If swallowed, DO NOT induce vomiting.<br>Get medical attention if symptoms occur.<br>Rinse mouth thoroughly with water. |  |  |
| 4.2 N       | Most im             | portant symptoms a                | nd e | effects, both acute   | e and delayed  |  |
|             | Risks               |                                   | :    | May cause dama exposure.  | ge to organs through prolonged or repeated   |  |
| 4.3 I       | ndicati             | on of any immediate               | med  | dical attention and   | d special treatment needed   |  |
|             | Treatm              | -                                 | :    |   | ically and supportively.   |  |
| SEC         |                     | 5: Firefighting mea               | sur  | es  |  |  |
|             |                     |                                   |      |   |  |  |
| 5.1 E       | -                   | ishing media                      |      |   |  |  |
|             | Suitabl             | e extinguishing media             | :    | Water spray<br>Alcohol-resistant<br>Carbon dioxide ((<br>Dry chemical   |  |  |
|             | Unsuita<br>media    | able extinguishing                | :    | None known.   |  |  |
| 5.2 5       | Special             | hazards arising from              | the  | e substance or mi   | xture  |  |
|             | Specific fighting   | c hazards during fire-            | :    | Exposure to com   | bustion products may be a hazard to health.  |  |
|             | Hazard<br>ucts      | lous combustion prod-             | :    | Nitrogen oxides (<br>Carbon oxides<br>Sulphur oxides<br>Chlorine compou   |  |  |
| 5.3 A       | Advice              | for firefighters                  |      |   |  |  |
|             | Specia<br>for firef | l protective equipment<br>ighters | :    |   | e, wear self-contained breathing apparatus.<br>tective equipment.  |  |
|             | Specific<br>ods     | c extinguishing meth-             | :    | cumstances and<br>Use water spray   | g measures that are appropriate to local cir-<br>the surrounding environment.<br>to cool unopened containers.<br>ged containers from fire area if it is safe to do |  |

# **SECTION 6: Accidental release measures**

## 6.1 Personal precautions, protective equipment and emergency procedures

| Personal precautions | : | Use personal protective equipment.                            |
|----------------------|---|---|
|                      |   | Follow safe handling advice (see section 7) and personal pro- |



# **Furosemide Injection Formulation**

| Version<br>3.4                | Revision Date:<br>28.09.2024 | SDS Number:<br>9372650-00008  | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021  |  |  |  |  |  |
|-------------------------------|------------------------------|---|--|--|--|--|--|--|
|                               |                              | tective equipm  | nent recommendations (see section 8).  |  |  |  |  |  |
| 6.2 Environmental precautions |                              |   |  |  |  |  |  |  |
| Environmental precautions :   |                              | Prevent furthe<br>Prevent sprea<br>barriers).<br>Retain and dis<br>If spillage ente   | <ul> <li>Avoid release to the environment.</li> <li>Prevent further leakage or spillage if safe to do so.</li> <li>Prevent spreading over a wide area (e.g. by containment or oil barriers).</li> <li>Retain and dispose of contaminated wash water.</li> <li>If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).</li> </ul>  |  |  |  |  |  |
| 6.3 Metho                     | ds and material for co       | ontainment and clea   | aning up   |  |  |  |  |  |
| Metho                         | ods for cleaning up          | For large spills<br>ment to keep r<br>be pumped, st<br>Clean up rema<br>bent.<br>Local or natior<br>posal of this m<br>employed in th<br>mine which rep<br>Sections 13 ar | <ul> <li>Soak up with inert absorbent material.</li> <li>For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.</li> <li>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.</li> <li>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li> </ul> |  |  |  |  |  |

# 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

# **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

| - |                         |   |   |
|---|-------------------------|---|---|
|   | Technical measures      | : | See Engineering measures under EXPOSURE<br>CONTROLS/PERSONAL PROTECTION section.  |
|   | Local/Total ventilation | : | Use only with adequate ventilation.   |
|   | Advice on safe handling | : | Do not breathe mist or vapours.   |
|   |                         |   | Do not swallow.   |
|   |                         |   | Avoid contact with eyes.  |
|   |                         |   | Avoid prolonged or repeated contact with skin.  |
|   |                         |   | Wash skin thoroughly after handling.  |
|   |                         |   | Handle in accordance with good industrial hygiene and safety  |
|   |                         |   | practice, based on the results of the workplace exposure as-<br>sessment  |
|   |                         |   | Do not eat, drink or smoke when using this product.   |
|   |                         |   | Take care to prevent spills, waste and minimize release to the environment.   |
|   | Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye<br>flushing systems and safety showers close to the working<br>place. When using do not eat, drink or smoke. Wash contami-<br>nated clothing before re-use. |
|   |                         |   | The effective operation of a facility should include review of  |
|   |                         |   |   |

UK REACH Regulations SI 2019/758



# **Furosemide Injection Formulation**

| Version<br>3.4                                | Revision Date: 28.09.2024  | SDS Nu<br>9372650              |  | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021   |  |  |  |
|---|--|--------------------------------|--|---|--|--|--|
|   |  | apprindus                      | opriate degov  | ols, proper personal protective equipment,<br>wning and decontamination procedures,<br>monitoring, medical surveillance and the<br>tive controls. |  |  |  |
| 7.2 Conditi                                   | 7.2 Conditions for safe storage, including any incompatibilities |                                |  |   |  |  |  |
| Requirements for storage areas and containers |  |                                |  | labelled containers. Store in accordance with onal regulations.   |  |  |  |
| Advice on common storage                      |  | Stroi<br>Self-<br>Orga<br>Expl | <ul> <li>Do not store with the following product types:</li> <li>Strong oxidizing agents</li> <li>Self-reactive substances and mixtures</li> <li>Organic peroxides</li> <li>Explosives</li> <li>Gases</li> </ul> |   |  |  |  |
| 7.3 Specifi                                   | c end use(s)   |                                |  |   |  |  |  |
| -   | ic use(s)  | : No d                         | ata available  |   |  |  |  |

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

#### **Occupational Exposure Limits**

| Components | CAS-No. | Value type (Form | Control parameters  | Basis    |
|------------|---------|------------------|---------------------|----------|
|            |         | of exposure)     |                     |          |
| Furosemide | 54-31-9 | TWA              | 200 µg/m3           | Internal |
|            |         | TWA              | OEB 2 (>=100 - 1000 | Internal |
|            |         |                  | ug/m3)              |          |

#### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

#### Personal protective equipment

| Eye/face protection         | : | Wear safety glasses with side shields or goggles.<br>If the work environment or activity involves dusty conditions,<br>mists or aerosols, wear the appropriate goggles.<br>Wear a faceshield or other full face protection if there is a<br>potential for direct contact to the face with dusts, mists, or<br>aerosols. |
|-----------------------------|---|---|
| Hand protection<br>Material | : | Chemical-resistant gloves   |
| Skin and body protection    | : | Work uniform or laboratory coat.  |



| Version<br>3.4 | Revision Date: 28.09.2024 | SDS Number:<br>9372650-00008 | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021  |
|----------------|---------------------------|------------------------------|--|
| Respi          | ratory protection         | sure assessm<br>ommended gu  | cal exhaust ventilation is not available or expo-<br>ent demonstrates exposures outside the rec-<br>udelines, use respiratory protection.<br>ould conform to BS EN 143 |
| Fil            | ter type                  | : Particulates ty            | rpe (P)  |

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

| information on basic physical                       | an | a chemical properti                    |
|---|----|--|
| Appearance<br>Colour                                | :  | Aqueous solution<br>yellow             |
| Odour<br>Odour Threshold                            | :  | No data available<br>No data available |
| рН  | :  | No data available                      |
| Melting point/freezing point                        | :  | No data available                      |
| Initial boiling point and boiling range             | :  | No data available                      |
| Flash point   | :  | No data available                      |
| Evaporation rate                                    | :  | No data available                      |
| Flammability (solid, gas)                           | :  | Not applicable                         |
| Upper explosion limit / Upper<br>flammability limit | :  | No data available                      |
| Lower explosion limit / Lower<br>flammability limit | :  | No data available                      |
| Vapour pressure                                     | :  | No data available                      |
| Relative vapour density                             | :  | No data available                      |
| Relative density                                    | :  | No data available                      |
| Density   | :  | No data available                      |
| Solubility(ies)<br>Water solubility                 |    | No data available                      |
| Partition coefficient: n-                           | :  | No data available                      |
| octanol/water<br>Auto-ignition temperature          | :  | No data available                      |
| Decomposition temperature                           | :  | No data available                      |
| Viscosity<br>Viscosity, kinematic                   | :  | No data available                      |
| Explosive properties                                | :  | Not explosive                          |
|   |    |  |



# **Furosemide Injection Formulation**

| Version<br>3.4            | Revision Date: 28.09.2024                     | SDS Number:<br>9372650-00008                                | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021 |  |  |
|---------------------------|---|---|---|--|--|
| Oxidi                     | zing properties                               | : The substance   | e or mixture is not classified as oxidizing.                      |  |  |
| 9.2 Other                 | information                                   |   |   |  |  |
| Flam                      | mability (liquids)                            | : No data availa  | : No data available   |  |  |
| Partie                    | cle size                                      | : Not applicable  |   |  |  |
| SECTIO                    | N 10: Stability and re                        | activity  |   |  |  |
| <b>10.1 Read</b><br>Not c | <b>tivity</b><br>lassified as a reactivity    | hazard.   |   |  |  |
|                           | nical stability<br>e under normal conditic    | ns.   |   |  |  |
| 10.3 Poss                 | bibility of hazardous re                      | actions   |   |  |  |
| Haza                      | rdous reactions                               | : Can react with  | n strong oxidizing agents.  |  |  |
|                           | <b>litions to avoid</b><br>litions to avoid   | : None known.   |   |  |  |
| 10.5 Inco                 | mpatible materials                            |   |   |  |  |
|                           | rials to avoid                                | : Oxidizing age   | nts   |  |  |
|                           | rdous decomposition<br>azardous decomposition | -   |   |  |  |
|                           | N 11: Toxicological i                         | •   | l.<br>  |  |  |
| OLOTIO                    |   | mormation   |   |  |  |
|                           | mation on toxicologic                         |   |   |  |  |
| Inforr<br>expo            | nation on likely routes c<br>sure             | of : Inhalation<br>Skin contact<br>Ingestion<br>Eye contact |   |  |  |
|                           | <b>e toxicity</b><br>lassified based on avail | able information.   |   |  |  |
| <u>Com</u>                | ponents:                                      |   |   |  |  |
|                           | <b>semide:</b><br>e oral toxicity             | : LD50 (Rat): 2,6   | 600 mg/kg   |  |  |

LD50 (Dog): 2,000 mg/kg

LD50 (Rabbit): 800 mg/kg



# **Furosemide Injection Formulation**

| Vers<br>3.4 | sion   | Revision Date: 28.09.2024                           |      | OS Number:<br>72650-00008   | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021 |
|-------------|--------|---|------|---|---|
|             |        | oxicity (other routes of stration)                  | :    | LD0 (Humans): 6<br>Application Route  |   |
|             |        |   |      | LD50 (Rat): 800 r<br>Application Route  |   |
|             |        | orrosion/irritation<br>ssified based on availa      | ble  | information.  |   |
|             |        | s eye damage/eye irri<br>ssified based on availa    |      |   |   |
|             | Respir | atory or skin sensitis                              | atio | n   |   |
|             |        | ensitisation<br>ssified based on availa             | ble  | information.  |   |
|             | -      | atory sensitisation<br>ssified based on availa      | ble  | information.  |   |
|             |        | <b>cell mutagenicity</b><br>ssified based on availa | ble  | information.  |   |
|             | Compo  | onents:   |      |   |   |
|             | Furose | emide:  |      |   |   |
|             | Genoto | oxicity in vitro                                    | :    | Test Type: Bacter<br>Result: negative   | ial reverse mutation assay (AMES)                                 |
|             |        |   |      |   | o mammalian cell gene mutation test<br>se lymphoma cells          |
|             |        |   |      | Test Type: DNA c<br>thesis in mammal<br>Test system: man<br>Result: negative                    |   |
|             |        |   |      |   | nosome aberration test in vitro<br>nese hamster ovary cells       |
|             |        |   |      | malian cells  | o sister chromatid exchange assay in mam-<br>nese hamster cells   |
|             | Genoto | oxicity in vivo                                     | :    | Test Type: Mamm<br>cytogenetic assay<br>Species: Mouse<br>Application Route<br>Result: negative |   |
|             |        |   |      | Test Type: Mutag  | enicity (in vivo mammalian bone-marrow                            |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Furosemide Injection Formulation**

| Version<br>3.4 | Revision Date: 28.09.2024                   |      | OS Number:<br>72650-00008  | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021   |
|----------------|---|------|--|---|
|                |   |      | cytogenetic test, o<br>Species: Chinese<br>Application Route<br>Result: negative |   |
|                | nogenicity<br>assified based on avai        | able | information  |   |
|                | oonents:                                    |      |  |   |
| Furos          | semide:                                     |      |  |   |
|                | cation Route<br>sure time<br>:L             | :    | Rat<br>Ingestion<br>104 weeks<br>16 mg/kg body we<br>equivocal                   | eight   |
|                | cation Route<br>sure time<br>:L             | :    | Mouse<br>Ingestion<br>2 Years<br>91 mg/kg body w<br>positive                     | eight   |
| -              | oductive toxicity<br>assified based on avai | able | information.   |   |
| Com            | oonents:                                    |      |  |   |
| Furos          | semide:                                     |      |  |   |
| Effect         | s on fertility                              | :    | Species: Rat<br>Application Route<br>General Toxicity                            | eneration reproduction toxicity study<br>: Ingestion<br>· Parent: NOAEL: 90 mg/kg body weight<br>s on reproduction parameters   |
|                |   |      | Species: Mouse<br>Application Route<br>General Toxicity                          | eneration reproduction toxicity study<br>: Ingestion<br>· Parent: NOAEL: 200 mg/kg body weight<br>s on reproduction parameters  |
| Effect<br>ment | s on foetal develop-                        | :    | Species: Rat<br>Application Route<br>General Toxicity I<br>Developmental To      | y/early embryonic development<br>e: Ingestion<br>Maternal: LOAEL: 50 mg/kg body weight<br>oxicity: NOAEL: 300 mg/kg body weight<br>otoxic effects, No teratogenic effects |
|                |   |      | Species: Mouse<br>Application Route  | y/early embryonic development<br>e: Ingestion<br>Maternal: LOAEL: 25 mg/kg body weight  |



| Version<br>3.4 | Revision Date: 28.09.2024 | SDS Number:<br>9372650-00008   | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021 |
|----------------|---------------------------|--|---|
|                |                           | Result: Maternal   | toxicity observed., Fetal effects                                 |
|                |                           | Test Type: Fertility/early embryonic development<br>Species: Rabbit<br>Application Route: Ingestion<br>General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight<br>Developmental Toxicity: LOAEL: 12.5 mg/kg body weight<br>Result: Maternal toxicity observed., Reduced number of viable<br>fetuses<br>Test Type: Fertility/early embryonic development<br>Species: Rabbit<br>Application Route: Ingestion<br>General Toxicity Maternal: LOAEL: 15 mg/kg body weight<br>Result: Maternal toxicity observed., No effects on foetal de-<br>velopment |   |
|                |                           |  |   |

### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### Components:

#### **Furosemide:**

| Exposure routes<br>Target Organs |   | Ingestion<br>Kidnev   |
|----------------------------------|---|---|
| Assessment                       | : | Shown to produce significant health effects in animals at con-<br>centrations of 10 mg/kg bw or less. |

### Repeated dose toxicity

#### **Components:**

#### Furosemide:

| Species :           | Dog                                      |
|---------------------|--|
| NOAEL :             | 4 mg/kg                                  |
| LOAEL :             | 8 mg/kg                                  |
| Application Route : | Ingestion                                |
| Exposure time :     | 12 Months                                |
| Target Organs :     | Kidney                                   |
| Symptoms :          | Blood disorders                          |
| Remarks :           | Significant toxicity observed in testing |

#### Aspiration toxicity

Not classified based on available information.

#### Experience with human exposure

#### **Components:**

Furosemide:

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Furosemide Injection Formulation**

| Version                              | Revision Date: 28.09.2024 | SDS Number:   | Date of last issue: 06.04.2024   |
|--------------------------------------|---------------------------|---|--|
| 3.4                                  |                           | 9372650-00008   | Date of first issue: 27.08.2021  |
| Inhala<br>Skin c<br>Eye ca<br>Ingest | ontact                    | : Remarks: May i<br>: Remarks: May c<br>: Symptoms: Kidr<br>ance, dry mouth | be harmful if inhaled.<br>rritate skin.<br>cause eye irritation.<br>hey disorders, Headache, electrolyte imbal-<br>n, hearing loss, Irregular cardiac activity, Gas-<br>urbance, hypotension |

### **SECTION 12: Ecological information**

#### 12.1 Toxicity

**Components:** 

### Furosemide:

Toxicity to fish

: LC50 : 500 mg/l Exposure time: 96 h

#### 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

#### **Components:**

### Furosemide:

Partition coefficient: n- : log Pow: 2.03 octanol/water

#### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment :

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

### Product:

| Endocrine disrupting poten- | : | This substance/mixture does not contain components consid-   |
|-----------------------------|---|--|
| tial                        |   | ered to have endocrine disrupting properties for environment |
|                             |   | according to UK REACH Article 57(f).                         |

# **SECTION 13: Disposal considerations**

:

### 13.1 Waste treatment methods

Product

Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes 14.1 UN number

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Furosemide Injection Formulation**

| Version | Revision Date: 28.09.2024 | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|---------------------------|---|---|
| 3.4     |                           | 9372650-00008   | Date of first issue: 27.08.2021   |
| Conta   | aminated packaging        | Waste codes s<br>discussion with<br>Do not dispose<br>Empty containe<br>dling site for re | t specific, but application specific.<br>hould be assigned by the user, preferably in<br>the waste disposal authorities.<br>of waste into sewer.<br>ers should be taken to an approved waste han-<br>cycling or disposal.<br>e specified: Dispose of as unused product. |

ADN Not regulated as a dangerous good : ADR Not regulated as a dangerous good : RID Not regulated as a dangerous good : IMDG Not regulated as a dangerous good : ΙΑΤΑ • Not regulated as a dangerous good 14.2 UN proper shipping name ADN : Not regulated as a dangerous good ADR Not regulated as a dangerous good : RID Not regulated as a dangerous good : IMDG Not regulated as a dangerous good : ΙΑΤΑ Not regulated as a dangerous good 14.3 Transport hazard class(es) ADN Not regulated as a dangerous good : ADR : Not regulated as a dangerous good RID Not regulated as a dangerous good : IMDG Not regulated as a dangerous good : ΙΑΤΑ Not regulated as a dangerous good : 14.4 Packing group ADN Not regulated as a dangerous good : ADR Not regulated as a dangerous good : RID Not regulated as a dangerous good : IMDG Not regulated as a dangerous good : IATA (Cargo) Not regulated as a dangerous good : IATA (Passenger) : Not regulated as a dangerous good

## 14.5 Environmental hazards

Not regulated as a dangerous good



| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.4     | 28.09.2024     | 9372650-00008 | Date of first issue: 27.08.2021 |

### 14.6 Special precautions for user

UK REACH Regulations SI 2019/758

Not applicable

## **14.7 Transport in bulk according to Annex II of Marpol and the IBC Code** Remarks : Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

## 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

| UK REACH List of restrictions (Annex 17)  | :   | Conditions of restriction for the fol-<br>lowing entries should be considered:<br>Number on list 3  |
|---|-----|---|
|   |     | Substance(s) or mixture(s) are listed<br>here according to their appearance<br>in the regulation, irrespective of their<br>use/purpose or the conditions of the<br>restriction. Please refer to the condi-<br>tions in corresponding Regulation to<br>determine whether an entry is appli-<br>cable to the placing on the market or<br>not. |
| UK REACH Candidate list of substances of very high<br>concern (SVHC) for Authorisation                          | :   | Not applicable  |
| The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain) | :   | Not applicable  |
| Regulation (EC) on substances that deplete the ozone layer  | :   | Not applicable  |
| UK REACH List of substances subject to authorisation (Annex XIV)  | :   | Not applicable  |
| GB Export and import of hazardous chemicals - Prior<br>Informed Consent (PIC) Regulation                        | :   | Not applicable  |
| Control of Major Accident Hazards Regulations 2015 (CC<br>Not applicable  | OMA | NH)   |

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

#### The components of this product are reported in the following inventories:

| AICS  | : | not determined |
|-------|---|----------------|
| DSL   | : | not determined |
| IECSC | : | not determined |

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

:



# **Furosemide Injection Formulation**

| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.4     | 28.09.2024     | 9372650-00008 | Date of first issue: 27.08.2021 |

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

| <b>SECTION 16</b> | : Other | information |
|-------------------|---------|-------------|
|-------------------|---------|-------------|

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

#### Full text of H-Statements

H372

: Causes damage to organs through prolonged or repeated exposure.

#### Full text of other abbreviations

STOT RE

Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-



| Version<br>3.4                   | Revision Date: 28.09.2024 | SDS Number:<br>9372650-00008 | Date of last issue: 06.04.2024<br>Date of first issue: 27.08.2021 |
|----------------------------------|---------------------------|------------------------------|---|
| Sheet cy, http://echa.europa.eu/ |                           |                              |   |
| Class                            | sification of the mixt    | ure:                         | Classification procedure:   |
| STO                              | ۲RE 2                     | H373                         | Calculation method  |
|                                  |                           |                              | ·   |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN